{
  "schemaVersion": 1,
  "organisationId": "O-7a6119980a2b4a9899c101053d139150",
  "slug": "swedish-orphan-biovitrum",
  "name": "SWEDISH ORPHAN BIOVITRUM",
  "updatedAt": "2026-03-20T02:22:34.884975Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company headquartered in Stockholm that focuses on rare and debilitating diseases. Its core business is the development, commercialization and supply of medicines in haematology, immunology and specialty care, and its portfolio includes products such as Elocta, Alprolix, Doptelet, Aspaveli/Empaveli, Kineret, Gamifant and Orfadin.[P-2dfa1f0376834fe19d7566b9ca348bd1][P-bff0626305d04fceb47394334f262193][P-2a79c85648954701a3597344c3488c78] Sobi states that its mission is to transform the lives of people with rare and debilitating diseases, with an emphasis on expanding access to innovative therapies for eligible patients.[P-267bd556bd63423a99b969cba1877c09]\n[P-2dfa1f0376834fe19d7566b9ca348bd1][P-bff0626305d04fceb47394334f262193][P-2a79c85648954701a3597344c3488c78][P-267bd556bd63423a99b969cba1877c09][P-39c10aacafa1415da5841bedc37d0b57][P-3604b8aad94f4756b959c1a113be7dca]",
      "updatedAt": "2026-03-20T02:22:34.884975Z"
    },
    {
      "type": "PRODUCTS",
      "text": "Sobi’s product portfolio is centered on rare-disease medicines with a particularly detailed haematology lineup. Altuvoct (efanesoctocog alfa) is described as the first high-sustained factor VIII replacement therapy for haemophilia A, designed to maintain near-normal factor activity for a significant portion of the week with once-weekly dosing. Elocta (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) are recombinant extended half-life clotting factor VIII and IX therapies for haemophilia A and B, respectively. Doptelet (avatrombopag) is an oral thrombopoietin receptor agonist that increases platelet count in thrombocytopenia, while Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 therapy for paroxysmal nocturnal haemoglobinuria. The portfolio also includes Vonjo (pacritinib), an oral targeted kinase inhibitor for certain myelofibrosis patients with low platelet counts, and Zynlonta (loncastuximab tesirine) for adults with relapsed or refractory diffuse large B-cell lymphoma.[T-fe1407786028438bad65edb4693b361b][T-eff82cf65e9f419aaaf90e5c26f2fa60]\n\nIn immunology and respiratory indications, Kineret (anakinra) is a recombinant protein that blocks interleukin-1α and interleukin-1β by binding to interleukin-1 type 1 receptors, and Gamifant (emapalumab) is a monoclonal antibody that neutralises interferon gamma for ultra-rare hyperinflammatory syndromes. Synagis (palivizumab) is a monoclonal antibody used to prevent serious RSV lower respiratory tract infections in high-risk infants and young children, while Beyfortus (nirsevimab) is a single-dose, long-acting antibody intended to protect newborns and infants during their first RSV season and certain children up to 24 months in their second season.[T-ed41486b47334350a3ac5fc1c1cfde55][T-fe1407786028438bad65edb4693b361b][T-eff82cf65e9f419aaaf90e5c26f2fa60] Among products with disclosed revenue mix, Elocta accounted for 19% of total revenue in 2024, Doptelet 15%, Kineret 11%, Gamifant 7%, Aspaveli/Empaveli 4%, and Synagis 2%.[P-7c2f28820bba42acb596ca1cb48ee56c][P-a4078828eab448f689497a1e5a72bbdb][P-1e9396591aa4497e90120c40408b1ccb][P-f0634aa1b6b9426e8c0eaa3df7e85c14][P-84671a8af92146fd834ed348de7889a7][P-ab79195be2a34ddfbb92b7f3b9d28b84]\n\nIts specialty-care products include Orfadin (nitisinone), which treats hereditary tyrosinaemia type 1 by blocking tyrosine breakdown and thereby reducing toxic tyrosine by-products; treatment requires a special diet, and the medicine is also used for alkaptonuria. Tegsedi (inotersen) is used for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and Waylivra (volanesorsen) reduces triglyceride levels in genetically confirmed familial chylomicronaemia syndrome. In addition to direct medicine sales, Sobi’s haemophilia business includes royalty income tied to Altuviiio, and it receives royalties on Sanofi’s US sales of Beyfortus; the company also provides sales and marketing services for some partner medicines under contractual service-fee arrangements.[T-ed41486b47334350a3ac5fc1c1cfde55][T-eff82cf65e9f419aaaf90e5c26f2fa60][P-ad9f436b118141f4b86292193fa7baeb][P-2c8a960cc5d447d38dce77218e06d14b][P-be9654480b1644f6b4f9fc479dfcffad]\n[T-fe1407786028438bad65edb4693b361b][T-eff82cf65e9f419aaaf90e5c26f2fa60][T-ed41486b47334350a3ac5fc1c1cfde55][P-7c2f28820bba42acb596ca1cb48ee56c][P-a4078828eab448f689497a1e5a72bbdb][P-1e9396591aa4497e90120c40408b1ccb][P-f0634aa1b6b9426e8c0eaa3df7e85c14][P-84671a8af92146fd834ed348de7889a7][P-ab79195be2a34ddfbb92b7f3b9d28b84][P-ad9f436b118141f4b86292193fa7baeb][P-2c8a960cc5d447d38dce77218e06d14b][P-be9654480b1644f6b4f9fc479dfcffad]",
      "updatedAt": "2026-03-20T02:22:34.884975Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Swedish Orphan Biovitrum (Sobi) is headquartered in Stockholm, Sweden, and reports a direct or indirect presence in around 30 countries, with medicines delivered beyond those markets as well.[P-2dfa1f0376834fe19d7566b9ca348bd1][P-b73a036e6f764fa4a9bb209bb59cc886] Its legal-entity and office footprint spans much of Europe, North America, the Middle East and parts of Asia-Pacific, including Sweden, Denmark, Finland, France, Germany, Italy, Spain, the UK, Switzerland, the Netherlands, Portugal, Belgium, Austria, Greece, the Czech Republic, Norway, the US, Canada, the UAE, China, Japan, South Korea and Australia.[T-2cd372bd912e46018b3ed7322e605853]\n\nRevenue is reported by customer geography. In 2024, Europe was the largest reported sales region at SEK 9,690 million, followed by North America at SEK 8,513 million and International markets at SEK 2,925 million; an additional SEK 4,899 million was reported in “Other,” which refers to royalties on Sanofi sales and is stated to be attributable mainly to North America.[T-ca22308ea03c42bdada99cb5228c9826][P-3e094d6e5d0b42aeb48c02e60c2a4377][P-d24fb0d91c974d3db184dd7ed7744776] Sobi had 1,840 employees at year-end 2024, with the largest disclosed employee concentrations in the US (459), Sweden (340), Switzerland (230), Germany (125), Central and Eastern Europe (105), the UK (89), Italy (84), France (81), Spain (65), the United Arab Emirates (58) and Russia (50).[T-1d9b14f0f4aa44139a1702f141946d8b]\n[P-2dfa1f0376834fe19d7566b9ca348bd1][P-b73a036e6f764fa4a9bb209bb59cc886][T-2cd372bd912e46018b3ed7322e605853][T-ca22308ea03c42bdada99cb5228c9826][P-3e094d6e5d0b42aeb48c02e60c2a4377][P-d24fb0d91c974d3db184dd7ed7744776][T-1d9b14f0f4aa44139a1702f141946d8b]",
      "updatedAt": "2026-03-20T02:22:34.884975Z"
    },
    {
      "type": "SEGMENTS",
      "text": "Swedish Orphan Biovitrum reports three operating segments: Haematology, Immunology and Specialty Care, and states that internal reporting to the CEO is organised on this basis, with no sales between segments [P-c46ad38312524db1972178e2189d4add][P-746f30a11ffd4a828a4209c3025479bf].\n\nHaematology is the largest segment and focuses on therapies for haemophilia, thrombocytopenia and other serious blood disorders [P-86c3c4f36d0040daa632816cb8c6e30c][P-60f496a3fa4342e4911547cdc3fcf9da]. It generated SEK 16,429m of 2024 revenue, which is approximately 63% of total segment revenue [T-32a7d0e307fe4508acd6ce5283c36794]. Immunology focuses on therapies for auto-inflammatory and auto-immune conditions [P-595163f226a44d0ab562166e00e21f88]. It generated SEK 8,332m, or about 32% of total segment revenue [T-32a7d0e307fe4508acd6ce5283c36794]. Specialty Care is focused on rare genetic and metabolic diseases [P-2a01a7a7ae0941a4b750c6b19e2fc7e0]. It generated SEK 1,267m, or roughly 5% of total segment revenue [T-32a7d0e307fe4508acd6ce5283c36794].\n[P-c46ad38312524db1972178e2189d4add][P-746f30a11ffd4a828a4209c3025479bf][P-86c3c4f36d0040daa632816cb8c6e30c][P-60f496a3fa4342e4911547cdc3fcf9da][P-595163f226a44d0ab562166e00e21f88][P-2a01a7a7ae0941a4b750c6b19e2fc7e0][T-32a7d0e307fe4508acd6ce5283c36794]",
      "updatedAt": "2026-03-20T02:22:34.884975Z"
    },
    {
      "type": "HISTORY",
      "text": "Swedish Orphan Biovitrum (Sobi) traces its roots to Swedish biologics activities dating back to the 1930s. One of its main predecessors, Biovitrum, was created in 2001 when several Pharmacia business units were brought together and spun out as a standalone company. In November 2009, Biovitrum and Swedish Orphan were combined to form Swedish Orphan Biovitrum, and in June 2010 the company adopted the name Swedish Orphan Biovitrum AB (publ), or Sobi. [https://www.sobi.com/en/history][https://www.sobi.com/germany/de/ueber-sobi/unternehmensgeschichte][https://www.sobi.com/en/press-releases/creation-new-niche-specialty-pharmaceutical-company-focusedon-rare-diseases-strong][https://www.sobi.com/en/press-releases/change-company-name-biovitrum-ab-publ-1412603]\n\nBefore and around the merger, Biovitrum expanded its specialty-pharma portfolio through a 2008 deal with Amgen covering Kineret, Kepivance and Stemgen. Sobi later strengthened its haemophilia franchise with the European approval of Elocta in November 2015 and Alprolix in 2016. [https://www.sobi.com/en/press-releases/biovitrum-and-amgen-announce-close-product-acquisition-deal-1412729][P-a374ae28011a444e96192206bd54b440][https://www.sobi.com/en/press-releases/alprolixr-rfixfc-approved-eu-treatment-haemophilia-b-1415148]\n\nIn 2017, Guido Oelkers was appointed president and CEO. The company then expanded further in the US by integrating the Synagis business after acquiring US rights from AstraZeneca, and in November 2019 it completed the acquisition of Dova Pharmaceuticals, adding Doptelet and helping build a broader global haematology platform. [https://www.sobi.com/en/press-releases/guido-oelkers-appointed-president-and-ceo-sobi-1488644][P-93223c5effac4e0d9579cfd0ca932e48][P-e1cdc3c230814462a28beacf038e6598][P-a2711cc1d31d44f091d2b45c893d7c91]\n[P-a374ae28011a444e96192206bd54b440][P-93223c5effac4e0d9579cfd0ca932e48][P-e1cdc3c230814462a28beacf038e6598][P-a2711cc1d31d44f091d2b45c893d7c91][https://www.sobi.com/en/history][https://www.sobi.com/germany/de/ueber-sobi/unternehmensgeschichte][https://www.sobi.com/en/press-releases/creation-new-niche-specialty-pharmaceutical-company-focusedon-rare-diseases-strong][https://www.sobi.com/en/press-releases/change-company-name-biovitrum-ab-publ-1412603][https://www.sobi.com/en/press-releases/biovitrum-and-amgen-announce-close-product-acquisition-deal-1412729][https://www.sobi.com/en/press-releases/alprolixr-rfixfc-approved-eu-treatment-haemophilia-b-1415148][https://www.sobi.com/en/press-releases/guido-oelkers-appointed-president-and-ceo-sobi-1488644]",
      "updatedAt": "2026-03-20T02:22:34.884975Z"
    }
  ],
  "sources": [
    {
      "id": "P-2dfa1f0376834fe19d7566b9ca348bd1",
      "href": "https://app.finbar.com/go?id=P-2dfa1f0376834fe19d7566b9ca348bd1",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p4",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 4
    },
    {
      "id": "P-bff0626305d04fceb47394334f262193",
      "href": "https://app.finbar.com/go?id=P-bff0626305d04fceb47394334f262193",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p5",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 5
    },
    {
      "id": "P-2a79c85648954701a3597344c3488c78",
      "href": "https://app.finbar.com/go?id=P-2a79c85648954701a3597344c3488c78",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p32",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 32
    },
    {
      "id": "P-267bd556bd63423a99b969cba1877c09",
      "href": "https://app.finbar.com/go?id=P-267bd556bd63423a99b969cba1877c09",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p10",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 10
    },
    {
      "id": "P-39c10aacafa1415da5841bedc37d0b57",
      "href": "https://app.finbar.com/go?id=P-39c10aacafa1415da5841bedc37d0b57",
      "label": "SWEDISH ORPHAN BIOVITRUM — Presentation (2024 Y), p4",
      "documentId": "D-4f7b0d232d0d4b7b872d53eab7fc2712",
      "page": 4
    },
    {
      "id": "P-3604b8aad94f4756b959c1a113be7dca",
      "href": "https://app.finbar.com/go?id=P-3604b8aad94f4756b959c1a113be7dca",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p102",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 102
    },
    {
      "id": "T-fe1407786028438bad65edb4693b361b",
      "href": "https://app.finbar.com/go?id=T-fe1407786028438bad65edb4693b361b",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p164",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 164
    },
    {
      "id": "T-eff82cf65e9f419aaaf90e5c26f2fa60",
      "href": "https://app.finbar.com/go?id=T-eff82cf65e9f419aaaf90e5c26f2fa60",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p166",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 166
    },
    {
      "id": "T-ed41486b47334350a3ac5fc1c1cfde55",
      "href": "https://app.finbar.com/go?id=T-ed41486b47334350a3ac5fc1c1cfde55",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p165",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 165
    },
    {
      "id": "P-7c2f28820bba42acb596ca1cb48ee56c",
      "href": "https://app.finbar.com/go?id=P-7c2f28820bba42acb596ca1cb48ee56c",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p14",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 14
    },
    {
      "id": "P-a4078828eab448f689497a1e5a72bbdb",
      "href": "https://app.finbar.com/go?id=P-a4078828eab448f689497a1e5a72bbdb",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p14",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 14
    },
    {
      "id": "P-1e9396591aa4497e90120c40408b1ccb",
      "href": "https://app.finbar.com/go?id=P-1e9396591aa4497e90120c40408b1ccb",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p15",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 15
    },
    {
      "id": "P-f0634aa1b6b9426e8c0eaa3df7e85c14",
      "href": "https://app.finbar.com/go?id=P-f0634aa1b6b9426e8c0eaa3df7e85c14",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p15",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 15
    },
    {
      "id": "P-84671a8af92146fd834ed348de7889a7",
      "href": "https://app.finbar.com/go?id=P-84671a8af92146fd834ed348de7889a7",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p14",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 14
    },
    {
      "id": "P-ab79195be2a34ddfbb92b7f3b9d28b84",
      "href": "https://app.finbar.com/go?id=P-ab79195be2a34ddfbb92b7f3b9d28b84",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p15",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 15
    },
    {
      "id": "P-ad9f436b118141f4b86292193fa7baeb",
      "href": "https://app.finbar.com/go?id=P-ad9f436b118141f4b86292193fa7baeb",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p14",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 14
    },
    {
      "id": "P-2c8a960cc5d447d38dce77218e06d14b",
      "href": "https://app.finbar.com/go?id=P-2c8a960cc5d447d38dce77218e06d14b",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p15",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 15
    },
    {
      "id": "P-be9654480b1644f6b4f9fc479dfcffad",
      "href": "https://app.finbar.com/go?id=P-be9654480b1644f6b4f9fc479dfcffad",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p93",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 93
    },
    {
      "id": "P-b73a036e6f764fa4a9bb209bb59cc886",
      "href": "https://app.finbar.com/go?id=P-b73a036e6f764fa4a9bb209bb59cc886",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p4",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 4
    },
    {
      "id": "T-2cd372bd912e46018b3ed7322e605853",
      "href": "https://app.finbar.com/go?id=T-2cd372bd912e46018b3ed7322e605853",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p119",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 119
    },
    {
      "id": "T-ca22308ea03c42bdada99cb5228c9826",
      "href": "https://app.finbar.com/go?id=T-ca22308ea03c42bdada99cb5228c9826",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p33",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 33
    },
    {
      "id": "P-3e094d6e5d0b42aeb48c02e60c2a4377",
      "href": "https://app.finbar.com/go?id=P-3e094d6e5d0b42aeb48c02e60c2a4377",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p33",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 33
    },
    {
      "id": "P-d24fb0d91c974d3db184dd7ed7744776",
      "href": "https://app.finbar.com/go?id=P-d24fb0d91c974d3db184dd7ed7744776",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p102",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 102
    },
    {
      "id": "T-1d9b14f0f4aa44139a1702f141946d8b",
      "href": "https://app.finbar.com/go?id=T-1d9b14f0f4aa44139a1702f141946d8b",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p105",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 105
    },
    {
      "id": "P-c46ad38312524db1972178e2189d4add",
      "href": "https://app.finbar.com/go?id=P-c46ad38312524db1972178e2189d4add",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p92",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 92
    },
    {
      "id": "P-746f30a11ffd4a828a4209c3025479bf",
      "href": "https://app.finbar.com/go?id=P-746f30a11ffd4a828a4209c3025479bf",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p100",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 100
    },
    {
      "id": "P-86c3c4f36d0040daa632816cb8c6e30c",
      "href": "https://app.finbar.com/go?id=P-86c3c4f36d0040daa632816cb8c6e30c",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p5",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 5
    },
    {
      "id": "P-60f496a3fa4342e4911547cdc3fcf9da",
      "href": "https://app.finbar.com/go?id=P-60f496a3fa4342e4911547cdc3fcf9da",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p13",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 13
    },
    {
      "id": "T-32a7d0e307fe4508acd6ce5283c36794",
      "href": "https://app.finbar.com/go?id=T-32a7d0e307fe4508acd6ce5283c36794",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p100",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 100
    },
    {
      "id": "P-595163f226a44d0ab562166e00e21f88",
      "href": "https://app.finbar.com/go?id=P-595163f226a44d0ab562166e00e21f88",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p13",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 13
    },
    {
      "id": "P-2a01a7a7ae0941a4b750c6b19e2fc7e0",
      "href": "https://app.finbar.com/go?id=P-2a01a7a7ae0941a4b750c6b19e2fc7e0",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2024 Y), p13",
      "documentId": "D-3014aab365af42d0865ba398ee26a34a",
      "page": 13
    },
    {
      "id": "https://www.sobi.com/en/history",
      "href": "https://www.sobi.com/en/history",
      "label": "www.sobi.com"
    },
    {
      "id": "https://www.sobi.com/germany/de/ueber-sobi/unternehmensgeschichte",
      "href": "https://www.sobi.com/germany/de/ueber-sobi/unternehmensgeschichte",
      "label": "www.sobi.com"
    },
    {
      "id": "https://www.sobi.com/en/press-releases/creation-new-niche-specialty-pharmaceutical-company-focusedon-rare-diseases-strong",
      "href": "https://www.sobi.com/en/press-releases/creation-new-niche-specialty-pharmaceutical-company-focusedon-rare-diseases-strong",
      "label": "www.sobi.com"
    },
    {
      "id": "https://www.sobi.com/en/press-releases/change-company-name-biovitrum-ab-publ-1412603",
      "href": "https://www.sobi.com/en/press-releases/change-company-name-biovitrum-ab-publ-1412603",
      "label": "www.sobi.com"
    },
    {
      "id": "https://www.sobi.com/en/press-releases/biovitrum-and-amgen-announce-close-product-acquisition-deal-1412729",
      "href": "https://www.sobi.com/en/press-releases/biovitrum-and-amgen-announce-close-product-acquisition-deal-1412729",
      "label": "www.sobi.com"
    },
    {
      "id": "P-a374ae28011a444e96192206bd54b440",
      "href": "https://app.finbar.com/go?id=P-a374ae28011a444e96192206bd54b440",
      "label": "SWEDISH ORPHAN BIOVITRUM — Presentation (2015 Y), p13",
      "documentId": "D-d0daa7da289b4cbf8d4e26d98b669071",
      "page": 13
    },
    {
      "id": "https://www.sobi.com/en/press-releases/alprolixr-rfixfc-approved-eu-treatment-haemophilia-b-1415148",
      "href": "https://www.sobi.com/en/press-releases/alprolixr-rfixfc-approved-eu-treatment-haemophilia-b-1415148",
      "label": "www.sobi.com"
    },
    {
      "id": "https://www.sobi.com/en/press-releases/guido-oelkers-appointed-president-and-ceo-sobi-1488644",
      "href": "https://www.sobi.com/en/press-releases/guido-oelkers-appointed-president-and-ceo-sobi-1488644",
      "label": "www.sobi.com"
    },
    {
      "id": "P-93223c5effac4e0d9579cfd0ca932e48",
      "href": "https://app.finbar.com/go?id=P-93223c5effac4e0d9579cfd0ca932e48",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2019 Y), p18",
      "documentId": "D-a4875592616140b998799906c459ffaf",
      "page": 18
    },
    {
      "id": "P-e1cdc3c230814462a28beacf038e6598",
      "href": "https://app.finbar.com/go?id=P-e1cdc3c230814462a28beacf038e6598",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2019 Y), p92",
      "documentId": "D-a4875592616140b998799906c459ffaf",
      "page": 92
    },
    {
      "id": "P-a2711cc1d31d44f091d2b45c893d7c91",
      "href": "https://app.finbar.com/go?id=P-a2711cc1d31d44f091d2b45c893d7c91",
      "label": "SWEDISH ORPHAN BIOVITRUM — Full financial report (2019 Y), p34",
      "documentId": "D-a4875592616140b998799906c459ffaf",
      "page": 34
    }
  ]
}